SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms

IF 2.8 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS American Journal of Cardiovascular Drugs Pub Date : 2023-08-24 DOI:10.1007/s40256-023-00602-8

Yali Zhang, Yufeng He, Siqi Liu, Li Deng, Yumei Zuo, Keming Huang, Bin Liao, Guang Li, Jian Feng

{"title":"SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms","authors":"Yali Zhang, Yufeng He, Siqi Liu, Li Deng, Yumei Zuo, Keming Huang, Bin Liao, Guang Li, Jian Feng","doi":"10.1007/s40256-023-00602-8","DOIUrl":null,"url":null,"abstract":"<div><p>Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium–glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults.</p></div>","PeriodicalId":7652,"journal":{"name":"American Journal of Cardiovascular Drugs","volume":"23 6","pages":"641 - 662"},"PeriodicalIF":2.8000,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiovascular Drugs","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s40256-023-00602-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 1

Abstract

Population aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium–glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of beneficial effects on cardiovascular disease. Experimental models of cardiovascular disease have shown that SGLT2i ameliorate the process of aging-related cardiovascular disease by inhibiting inflammation, reducing oxidative stress, and reversing endothelial dysfunction. In this review, we discuss the role of SGLT2i in aging-related cardiovascular disease and propose the use of SGLT2i to prevent and treat these conditions in older adults.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SGLT2抑制剂在衰老相关心血管疾病中的作用：潜在机制综述。

人口老龄化加上老年人对心血管疾病的易感性增加了动脉粥样硬化、心肌梗死、心力衰竭、心肌肥大、心肌纤维化、心律失常和高血压等疾病的发生率。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）最初是作为一种新型口服药物开发的，用于2型糖尿病患者。出乎意料的是，最近的研究表明，除了对高血糖的影响外，SGLT2i对心血管疾病也有多种有益作用。心血管疾病的实验模型表明，SGLT2i通过抑制炎症、减少氧化应激和逆转内皮功能障碍来改善衰老相关心血管疾病的过程。在这篇综述中，我们讨论了SGLT2i在衰老相关心血管疾病中的作用，并建议使用SGLT2i预防和治疗老年人的这些疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

American Journal of Cardiovascular Drugs 医学-心血管系统

CiteScore

6.70

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents. Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations. The American Journal of Cardiovascular Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.